What is Bonjesta, and what does “Spain license” mean?
Bonjesta is a brand of prescription medication used to treat nausea and vomiting in pregnancy. “Spain license” generally refers to the drug’s authorization by Spain’s medicines regulator (so it can be marketed and prescribed there), not a separate license for each company or country.
Who holds the marketing authorization for Bonjesta in Spain?
I don’t have the provided materials needed to confirm which company holds Bonjesta’s marketing authorization in Spain or whether “Duchesnay” (or “Duchesnay” spelled in other ways) is the license holder for that Spanish authorization.
How does Duchesnay fit in with Bonjesta?
“Duchesnay” is a company name that often appears in relation to drug products or distribution/marketing arrangements, but the user’s wording (“Bonjesta spain lisence duchesnay”) doesn’t specify whether you mean:
- the holder of the Spanish marketing authorization,
- the company responsible for commercialization in Spain,
- or a distributor/licensing partner.
Those are different roles, and the answer depends on which “license” you mean.
What to check to confirm the correct license holder in Spain
To verify who has the Spanish authorization/authorization holder (and whether Duchesnay is involved), you typically check:
- Spain’s AEMPS/CIMA product record for “Bonjesta” (shows marketing authorization holder/MAH), and/or
- the packaging insert and product registration details that list the MAH in Spain.
If you meant a patent or exclusivity license, where to look
If your real interest is whether Duchesnay has a patent or commercialization license related to Bonjesta in Spain (or whether exclusivity is expiring), DrugPatentWatch.com is a useful starting point for patent/exclusivity research: https://www.drugpatentwatch.com/
---
If you tell me what you mean by “lisence” (marketing authorization holder vs distributor vs patent/license), and whether you mean the Spanish label brand name exactly “Bonjesta,” I can help narrow down the right answer.